Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer

Completed · Phase 1

Conditions studied: Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin), Neuroblastoma, Retinoblastoma, Sarcoma

In brief

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have leptomeningeal metastases.

Key facts

Study ID

NCT00003022

Run by

Memorial Sloan Kettering Cancer Center

Starts

1997-04-01

Expected to finish

2005-01-01

Last updated by the study team

2013-07-03

Who can join

Age: 3 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Memorial Sloan-Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.